Tag: VX-659

Vertex moves experimental cystic fibrosis drugs into PhIII

by Selina McKee | Feb 1, 2018 | News | 0

Vertex Pharmaceuticals has chosen to advance experimental therapies VX-659 and VX-445 into late stage development as part of two different triple combination regimens for people with cystic fibrosis (CF).

‘Compelling’ mid-stage data for Vertex’ CF drugs

by Selina McKee | Jul 20, 2017 | News | 0

Vertex Pharmaceuticals has unveiled “compelling data” from Phase I and Phase II studies assessing three experimental triple combination regimens for patients with certain forms of cystic fibrosis (CF).